The paths of these two stars have intersected on several occasions due to their association with the luxury brand Bulgari
entertainment7 hours ago
India's Bharat Biotech has sought permission from India's drug regulator to conduct a phase-3 study for its intra-nasal Covid-19 vaccine as a booster dose on participants vaccinated with Covishield or Covaxin, official sources said on Monday.
India is yet to approve the use of the intranasal vaccine BBV154 developed by the Hyderabad-based company.
The company had in August received the Drug Controller General of India's (DCGI's) nod for conducting phase 2 clinical trials of the nasal vaccine.
"Bharat Biotech has put in an application seeking permission to conduct a study titled 'A Phase 3 Study to Evaluate the Safety and Immunogenicity of BBV154 and BBV152 as third dose (booster) to participants previously vaccinated with SARS-CoV-2 vaccines'," an official said.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. Bharat Biotech has in-licensed the technology from Washington University in St Louis, the US.
The company reports that the doses of the vaccine administered to healthy volunteers in the phase-1 clinical trial have been well tolerated. No serious adverse events were reported, the DBT had said.
Previously, the vaccine was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit a high level of neutralising antibodies in animal studies, it added.
ALSO READ:
On the government's stand over allowing the use of booster doses, Niti Aayog member (Health) Dr VK Paul had last week said these interventions and measures are driven by science, local epidemiology and resources.
"This time around, vaccine resources, broadly speaking, are in a good shape. What we are doing concurrently is engaging our scientific community to look at these issues on an ongoing basis. Have faith. When there is no resource constraint our epidemiology and scientific discourse will decide this. We have competent teams which are examining this, we should be going for this option where there is appropriate evidence at an appropriate time. But all this approach comes after we have provided primary vaccination coverage to the maximum possible population and that remains the foremost goal," he had said.
The Centre recently has informed Parliament that the National Expert Group on vaccine administration for Covid (NEGVAC) and National Technical Advisory Group on Immunization (NTAGI) are deliberating and considering scientific evidence related to justification for booster dose against Covid-19.
The paths of these two stars have intersected on several occasions due to their association with the luxury brand Bulgari
entertainment7 hours ago
The students' demands range from a ceasefire in Israel's war with Hamas to calls for universities to stop investing in Israeli enterprises
world7 hours ago
Despite Kohli's flowing form ahead of the T20 World Cup in June, pundits have raised concerns over his strike-rate
cricket7 hours ago
Saudi Arabia has begun to explore extracting lithium from sea water
business8 hours ago
Speaking after meeting Lebanese leaders, French foreign minister says there had been "a lot of progress" over the French proposals
mena8 hours ago
The three-shot winner from Japan says he is aiming to become a member of the PGA Tour in the future
sports8 hours ago
Big-hitting Nienaber falters at the finish to settle for secondwhile former Abu Dhabi resident David Horsey takes the third spot at Saadiyat Beach Golf Club
sports8 hours ago
The UAE is India's second-largest export destination after the US
economy9 hours ago